TY - JOUR
T1 - Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells
AU - Fernández-Rodríguez, Concepción
AU - Salar, Antonio
AU - Navarro, Alfons
AU - Gimeno, Eva
AU - Pairet, Silvia
AU - Camacho, Laura
AU - Ferraro, Mariana
AU - Serrano, Sergi
AU - Besses, Carles
AU - Bellosillo, Beatriz
AU - Sanchez-Gonzalez, Blanca
PY - 2016/3/3
Y1 - 2016/3/3
N2 - © 2015 © 2015 Informa UK, Ltd. Current standard-of-care therapy for diffuse large B-cell lymphoma (DLBCL) results in up to 40% of patients who either relapse or develop refractory disease. In this setting, further therapeutic improvements are needed. This study analyzed the in vitro effects of the combination of bendamustine with the histone deacetylase inhibitor vorinostat in DLBCL cells. This combination enhanced histone acetylation and double strand DNA breaks resulting in an additive to synergistic cytotoxic effect in both ABC-and GCB-type DLBCL cells, independently of their TP53 mutational status. These results support the rationale for considering bendamustine and vorinostat combination as a novel approach in DLBCL treatment.
AB - © 2015 © 2015 Informa UK, Ltd. Current standard-of-care therapy for diffuse large B-cell lymphoma (DLBCL) results in up to 40% of patients who either relapse or develop refractory disease. In this setting, further therapeutic improvements are needed. This study analyzed the in vitro effects of the combination of bendamustine with the histone deacetylase inhibitor vorinostat in DLBCL cells. This combination enhanced histone acetylation and double strand DNA breaks resulting in an additive to synergistic cytotoxic effect in both ABC-and GCB-type DLBCL cells, independently of their TP53 mutational status. These results support the rationale for considering bendamustine and vorinostat combination as a novel approach in DLBCL treatment.
KW - Bendamustine
KW - Diffuse large B-cell lymphoma
KW - Histone deacetylase inhibitor
KW - TP53
KW - Vorinostat
U2 - 10.3109/10428194.2015.1063143
DO - 10.3109/10428194.2015.1063143
M3 - Article
VL - 57
SP - 692
EP - 699
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 3
ER -